Long noncoding RNAs (lncRNAs) have recently been identified as crucial biomarkers of papillary thyroid cancer (PTC). In this study, we aimed to investigate the biological function and potential clinical role of lncRNA ENST00000494165 in PTC. From January 2019 to December 2019, 226 PTC patients who underwent preoperative thyroid USfine needle aspiration biopsy(USFNAB) and confirmed by postoperative pathology were enrolled at our hospital. Thyroid tissues were collected from FNAB samples and stored in the refrigerator at –80 ºC. qRTPCR (quantitative reverse transcriptasepolymerase chain reaction) analysis was performed to detect the relative expression level of ENST00000494165. CCK8 (Cell Counting Kit8) and colony formation assay were performed to detect the cell proliferation ability. Cell migration and invasion abilities were evaluated by transwell and scratch assay. We also evaluated the relation between the expression level of ENST00000494165 and the clinicopathological features of PTC. Functional assays demonstrated that the cell proliferation, migration and invasion abilities were all promoted in PTC cell lines when ENST00000494165 expression was overexpressed. The expression of ENST00000494165 in the lymph node metastasis group was significantly higher than that in nonlymph node metastasis group. High level expression of ENST00000494165 was significantly associated with lymph node metastasis of PTC(P < 0.001). The overexpression of ENST00000494165 promoted the progression, migration and invasion abilities of PTC and was significantly correlated with lymph node metastasis in PTC. ENST00000494165 could act as a possible promoter gene and a potential biomarker for PTC.
Keywords: Long noncoding RNA, ENST00000494165, Papillary thyroid cancer, Cell proliferation and invasion, Lymph node metastasis
Full text and supplemented materials
References
Batista, P.J. and Chang, H.Y., Long noncoding RNAs: Cellular address codes in development and disease, Cell, 2013, vol. 152, pp. 1298–1307.
Cabanillas, M.E., McFadden, D.G., and Durante, C., Thyroid cancer, Lancet, 2016, vol. 388, pp. 783–2795.
Chou, C.K., Liu, R.T., and Kang, H.Y., MicroRNA-146b: A novel biomarker and therapeutic target for human papillary thyroid cancer, Int. J. Mol. Sci., 2017, vol. 18, p. 636.
Davies, L. and Welch, H.G., Current thyroid cancer trends in the United States, JAMA Otolaryngol. Head Neck Surg., 2014, vol. 140, pp. 317–322.
Forrest, M.E. and Khalil, A.M., Review: Regulation of the cancer epigenome by long non-coding RNAs, Cancer Lett., 2017, vol. 407, pp. 106–112.
Gupta, R.A., Shah, N., Wang, K.C., et al., Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis, Nature, 2010, vol. 464, pp. 1071–1076.
Gutschner, T., Hämmerle, M., and Diederichs, S., MALAT1 — a paradigm for long noncoding RNA function in cancer, J. Mol. Med., 2013, vol. 91, pp. 791–801.
Huarte, M., The emerging role of lncRNAs in cancer, Nat. Med., 2015, vol. 21, pp. 1253–1261.
Kurebayashi, J., Tanaka, K., Otsuki, T., et al., All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1, J. Clin. Endocrinol. Metab., 2000, vol. 85, pp. 2889–2896.
Li, L., Liu, B., Wapinski, O.L., et al., Targeted disruption of Hotair leads to homeotic transformation and gene derepression, Cell Rep., 2013, vol. 5, pp. 3–12.
Li, G., Zhang, Y., Mao, J., et al., LncRNA TUC338 is overexpressed in prostate carcinoma and downregulates miR-466, Gene, 2019, vol. 707, pp. 224–230.
Liao, D., Lv, G., Wang, T., et al., Prognostic value of long non-coding RNA BLACAT1 in patients with papillary thyroid carcinoma, Cancer Cell Int., 2018, vol. 18, p. 47.
Liu, Y, Li, L, Liu, Z, et al., Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma, Cancer Biomarkers, 2018, vol. 22, pp. 727–732.
Ma, S., Jia, W., and Ni, S., MiR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1, Biochem. Biophys. Res. Commun., 2018, vol. 497, pp. 181–186.
Mercer, T.R., Dinger, M.E., and Mattick, J.S., Long non-coding RNAs: insights into functions, Nat. Rev. Genet., 2009, vol. 10, pp. 155–159.
Qin, Y., Sun, W., Zhang, H., et al., LncRNA GAS8-AS1 inhibits cell proliferation through ATG5-mediated autophagy in papillary thyroid cancer, Endocrine, 2018, vol. 59, pp. 555–564.
Rinn, J.L. and Chang, H.Y., Genome regulation by long noncoding RNAs, Annu. Rev. Biochem., 2012, vol. 81, pp. 145–166.
Siegel, R.L., Miller, K.D., and Jemal, A., Cancer Statistics, Ca-Cancer J. Clin., 2018, vol. 68, pp. 7–30
The cancer genome atlas research network. Integrated genomic characterization of papillary thyroid carcinoma, Cell, 2014, vol. 159, pp. 676–690.
Tripathi, V., Ellis, J.D., Shen, Z., et al., The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation, Mol. Cell, 2010, vol. 39, pp. 925–938.
Xia, E., Bhandari, A., Shen, Y., et al., LncRNA CCND2-AS1 promotes proliferation, migration, and invasion in papillary thyroid carcinoma, Biochem. Biophys. Res. Commun., 2018, vol. 496, pp. 628–632.
Yang, Z., Zhou, L., and Wu, L.M., Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation, Ann. Surg. Oncol., 2011, vol. 18, pp. 1243–1250.
Zhou, T., Zhong, M., Zhang, S., et al., LncRNA CASC2 expression is down-regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway, Cancer Biomarkers, 2018, vol. 23, pp. 185–191.